TherapeuticsMD Announces Poster Presentations at International Society for the Study of Women’s Sexual Health Annual Meeting

Sigue a La Raza en Facebook

BOCA RATON, Fla.–(BUSINESS WIRE)–TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women’s healthcare
company, today announced that poster presentations related to the Phase
3 Rejoice Trial of TX-004HR, the Company’s investigational,
applicator-free vaginal estradiol softgel capsule for the treatment of
moderate to severe dyspareunia (vaginal pain during sexual intercourse),
a symptom of vulvar and vaginal atrophy (VVA) due to menopause, will be
made at the International Society for the Study of Women’s Sexual Health
(ISSWSH) Annual Meeting 2016, taking place in Charleston, South Carolina
on February 25-28.

Ginger Constantine, MD, President of EndoRheum Consultants and a
consultant to TherapeuticsMD, will present a poster titled “Rejoice
Trial: evaluation of an applicator-free vaginal estradiol softgel
capsule for the treatment of postmenopausal dyspareunia associated with
vulvar and vaginal atrophy (VVA).”

Sheryl A. Kingsberg, PhD, Chief of the Division of Behavioral Medicine
Department of OB/GYN at University Hospitals Case Medical Center in
Cleveland, will present a poster titled “Painful Sex, Why Women Do or
Don’t Seek Treatment.” This qualitative research was funded by
TherapeuticsMD.

Dr. Sebastian Mirkin, Chief Medical Officer of TherapeuticsMD, stated
“TherapeuticsMD is excited that the topline data from our Rejoice Trial
will be presented for the first time at a medical meeting. We believe
the highly statistically significant efficacy results, along with the
safety profile, demonstrated in the Rejoice Trial are very promising. We
continue to remain enthusiastic about the potential for TX-004HR, if
approved, to be a new treatment option with low systemic absorption for
women with VVA suffering from moderate to severe dyspareunia.”

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative healthcare company focused on
developing and commercializing products exclusively for women. With its
SYMBODA™ technology, TherapeuticsMD is developing advanced hormone
therapy pharmaceutical products to enable delivery of bio-identical
hormones through a variety of dosage forms and administration routes.
The company’s clinical development pipeline includes two phase 3
products. The company also manufactures and distributes branded and
generic prescription prenatal vitamins as well as over-the-counter
vitamins under the vitaMedMD® and BocaGreenMD®
brands. More information is available at the following websites: www.therapeuticsmd.com,
www.vitamedmdrx.com
and www.bocagreenmd.com.

Forward Looking Statements

This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include, but
are not limited to, statements relating to TherapeuticsMD’s objectives,
plans and strategies as well as statements, other than historical facts,
that address activities, events or developments that the company
intends, expects, projects, believes or anticipates will or may occur in
the future. These statements are often characterized by terminology such
as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,”
“plans,” “will,” “expects,” “estimates,” “projects,” “positioned,”
“strategy” and similar expressions and are based on assumptions and
assessments made in light of management’s experience and perception of
historical trends, current conditions, expected future developments and
other factors believed to be appropriate. Forward-looking statements in
this press release are made as of the date of this press release, and
the company undertakes no duty to update or revise any such statements,
whether as a result of new information, future events or otherwise.
Forward-looking statements are not guarantees of future performance and
are subject to risks and uncertainties, many of which are outside of the
company’s control. Important factors that could cause actual results,
developments and business decisions to differ materially from
forward-looking statements are described in the sections titled “Risk
Factors” in the company’s filings with the Securities and Exchange
Commission, including its most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and
include the following: the company’s ability to maintain or increase
sales of its products; the company’s ability to develop and
commercialize its hormone therapy drug candidates and obtain additional
financing necessary therefor; the length, cost and uncertain results of
the company’s clinical trials; the potential of adverse side effects or
other safety risks that could preclude the approval of the company’s
hormone therapy drug candidates; the company’s reliance on third parties
to conduct its clinical trials, research and development and
manufacturing; the availability of reimbursement from government
authorities and health insurance companies for the company’s products;
the impact of product liability lawsuits; the influence of extensive and
costly government regulation; the volatility of the trading price of the
company’s common stock and the concentration of power in its stock
ownership. PDF copies of the company’s historical press releases and
financial tables can be viewed and downloaded at its website:
www.therapeuticsmd.com/pressreleases.aspx.

Contacts

TherapeuticsMD, Inc.
Investors
Dan
Cartwright, 561-961-1900
Chief Financial Officer
Dan.Cartwright@TherapeuticsMD.com
or
Media
WCG
Elliot
Fox, 212-257-6724
Director, Media & Engagement
efox@w2ogroup.com